Results 251 to 260 of about 21,823 (309)
Haemodynamic assessment and therapeutic studies in portal hypertension and ascites [PDF]
, 1998 Stanley, Adrian John
core
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Treatment of Bleeding from Cardiofundal and Ectopic Varices in Cirrhosis. [PDF]
J Clin MedShalaby S +6 more
europepmc +1 more source
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis". [PDF]
Clin Mol HepatolSemmler G, Balcar L, Mandorfer M.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of Internal Medicine, 2021
BACKGROUND The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not ...
C. Bureau +15 more
semanticscholar +1 more source
BACKGROUND The efficacy of rifaximin in the secondary prevention of overt hepatic encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode in patients after transjugular intrahepatic portosystemic shunt (TIPS) has not ...
C. Bureau +15 more
semanticscholar +1 more source
Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement.
Radiology, 2022Background Sarcopenia is frequently found in patients with cirrhosis and is associated with liver dysfunction, cirrhosis-related complications, and poorer quality of life.
Jiacheng Liu +10 more
semanticscholar +1 more source
American Journal of Gastroenterology, 2021
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results.
Yong Lv +16 more
semanticscholar +1 more source
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results.
Yong Lv +16 more
semanticscholar +1 more source
Journal of Gastroenterology and Hepatology, 2021
A preemptive transjugular intrahepatic portosystemic shunt (p‐TIPSS) after acute variceal bleeding (AVB) is advocated. However, when compared with the current standard of care, the survival benefit of p‐TIPSS is questionable.
I. Hussain +4 more
semanticscholar +1 more source
A preemptive transjugular intrahepatic portosystemic shunt (p‐TIPSS) after acute variceal bleeding (AVB) is advocated. However, when compared with the current standard of care, the survival benefit of p‐TIPSS is questionable.
I. Hussain +4 more
semanticscholar +1 more source
Transjugular Intrahepatic Portosystemic Shunt
Contemporary Diagnostic Radiology, 2022Chronic liver disease is the 11th leading cause of mortality in the United States.1 Portal hypertension is a common endpoint for progressive liver disease, and can clinically manifest as refractory ascites, splenomegaly, and life-threatening esophageal ...
R. Tyagi +3 more
semanticscholar +1 more source
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS
Annual Review of Medicine, 1995▪ Abstract Management of bleeding esophageal varices due to portal hypertension has traditionally relied on endoscopic sclerotherapy and operative intervention with placement of a portosystemic shunt. Although percutaneous decompression of portal hypertension was investigated 25 years ago, it was not clinically feasible until recently.
Michael D. Dake +2 more
openaire +4 more sources